Weight-Loss Agents

Novo Nordisk to Cut 9,000 Jobs Globally as New CEO Targets $1.3B Savings by 2026

3 days ago talkbio0Tagged CEO, competition, Doustdar, eli lilly, Financial cost, Financial savings, layoffs, Nordisk, Ozempic, profit guidance, restructuring, Wegovy, Weight-Loss Agents

Novo Nordisk; layoffs; 9000 jobs; cost savings; CEO Doustdar; restructuring; weight-loss drugs; Wegovy; Ozempic; competition; Eli Lilly; profit guidance

Stockpiling Frenzy Prompts Lilly to Suspend UK Mounjaro Supply

2 weeks ago talkbio0Tagged eli lilly, Mounjaro, price hike, stockpiling, supply suspension, UK, Weight-Loss Agents

Eli Lilly; Mounjaro; stockpiling; UK; supply suspension; price hike; weight loss drug; tirzepatide

Novo Nordisk Maintains Edge in Obesity Pill Race as Lilly’s Pill Shows Modest Results

1 month ago talkbio0Tagged competition, Contraceptives, Oral, eli lilly, Glucagon-Like Peptide 1, Market, Nordisk, Obesity, oral semaglutide, orforglipron, Wegovy, Weight-Loss Agents, Zepbound

Novo Nordisk; Eli Lilly; obesity pill; oral semaglutide; orforglipron; weight loss drugs; Wegovy; Zepbound; GLP-1; market competition

Hims & Hers Stock Plunges 30% as Novo Nordisk Ends Wegovy Sales Deal

3 months ago talkbio0Tagged deceptive marketing, Glucagon-Like Peptide 1, Hims & Hers, Nordisk, partnership termination, stock plunge, Telemedicine, Wegovy, Weight-Loss Agents

Hims & Hers; stock plunge; Novo Nordisk; Wegovy; partnership termination; compounded GLP-1 drugs; deceptive marketing; telehealth; weight loss drugs

Pfizer’s Strategic Shift Post-Danuglipron: Exploring New Frontiers in Obesity Treatment

5 months ago talkbio0Tagged Danuglipron, GLP-1 receptor, GLP-1/GIP therapies, Injury of liver, Metabolic Diseases, Obesity, Pfizer, Pharmaceutical competition, pipeline, Weight-Loss Agents

Pfizer, danuglipron, obesity treatment, GLP-1 receptor agonist, liver injury, weight-loss drugs, GLP-1/GIP therapies, pharmaceutical competition, metabolic diseases, Viking Therapeutics, obesity pipeline

AbbVie Enters Obesity Market with $2.3 Billion Gubra Deal for Amylin Analog

6 months ago talkbio0Tagged AbbVie, Amylin Analog, GUB014295, GUBamy, Gubra, Obesity, pharmaceutical licensing, Weight-Loss Agents

AbbVie, Gubra, Obesity treatment, GUB014295 (GUBamy), Amylin analog, Weight loss drug, Pharmaceutical licensing deal

Pharma Ads Make Waves at Super Bowl 2025: Pfizer Wins Hearts, Hims & Hers Drives Engagement

7 months ago talkbio0Tagged Awareness, Dosage Forms, Health care facility, likeability, Malignant Neoplasms, Pfizer, Super Bowl 2025, Viewer Device, Weight-Loss Agents

Super Bowl 2025, pharmaceutical advertising, Pfizer, Hims & Hers, ad likeability, viewer engagement, healthcare marketing, cancer awareness, weight loss drugs